INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH

ISSN(print): 2833-213X, ISSN(online): 2833-2148

Volume 03 Issue 12 December 2024

DOI : 10.58806/ijhmr.2024.v3i12n05

Page No. 863-867

Pathophysiology And Clinical Manifestation of Cytokine Storm

Ali Y. Khudhair[1], Ahmed Hussein Zwamel[2], Maha Chasib Munshid[3], Ali A. Al-fahham[4]

[1] Department of Health Physics and Radiation Therapy Technical Engineering, Technical Engineering Najaf College, Al-Furat Al-Awsat Technical University 31001, Iraq

[2] Department Medical laboratory Technology, College of Medical Technology, The Islamic University, Najaf, Iraq

[3] Department of Pathological Analytics Science, College of Applied Medical Science, Shatrah University, Thi-Qar, 64001, Iraq

[4] Corresponding Author, Faculty of nursing, University of Kufa, Iraq

ABSTRACT: Cytokines are immune cell messengers. They are small proteins secreted by various cells, exerting very potent immunomodulatory and inflammatory effects. The diversity of their functions reveals their importance in healthy and pathological processes, including atherosclerosis, cancer, osteoarthritis, infectious diseases, and metabolic diseases. Currently, an important pathogenic factor for many severe diseases, especially infectious ones (such as COVID-19) is the cytokine storm. Only a comprehensive understanding of the mechanisms involved, combined with innovative therapeutics, will allow us to improve patient outcomes and intervene effectively. More research is still needed to bridge the many current knowledge gaps, improve treatment, and enhance care for patients in times of infectious disease crises. It focuses on recently available evidence on the cytokine storm mechanisms, outcomes, and possible treatment options concerning COVID-19 patients.

INTRODUCTION

Cytokines are small proteins secreted by different types of cells and are important in the regulation of immune responses and inflammation. Their wide range of functions is essential for health and pathogenesis in deadly diseases, modifying processes such as atherosclerosis, cancer, osteoarthritis, infectious diseases, and metabolic disorders. They have been recognized as principal inflammatory messengers in atherogenesis, playing a significant role in arterial biology and atherothrombotic events. Specific cytokines may indeed provide new treatment modalities that could be directed specifically at down-regulating the inflammation that exacerbates the vascular disease process. Also, the immune basis of allograft arteriosclerosis underscores the central role of inflammation in driving arterial hyperplasia, further illustrating that inflammation is at the heart of vascular pathology, whether conventional risk factors are present or not.

Furthermore, some recent studies have also investigated the crosstalk between NETs and cytokines in atherosclerosis. For instance, Warnatsch et al. (2015) showed that the presence of NETs can activate macrophages, which then produce pro-inflammatory cytokines, thus further enhancing atherosclerotic disease. Such interactions could be a cue for seeking new treatments in terms of targeting not only NETs directly but also cytokine signaling in the pathogenesis of cardiovascular diseases.

The contribution of pro-inflammatory cytokines to autoimmune diseases, such as osteoarthritis, has been well defined. Kapoor et al. (2011) notes the predominant roles of IL-1β, TNF-α, and IL-6 in the pathogenesis of osteoarthritis. Hence, results indicated that detailed knowledge of the cytokine network relating to such pathologies is a prerequisite for innovating new treatment procedures to deliberately suppress or modulate the action of inflammation.

A review by Neurath (2014), albeit in rather expert detail, clearly demonstrates the absolute critical involvement of a plethora of cytokines, reiterating their requirement not only to maintain homeostasis of the gut but also the pathologically disastrous consequences should dysregulation occur. This further underline the urgency for research into cytokine kinetics in conditions of chronic inflammation. More recently, attention has also begun to focus on the relationship between cytokines and psychiatric disorders, most notably Major Depressive Disorder (MDD). Köhler et al. (2017) review levels of cytokines and chemokines in MDD patients systematically, indicating a possible association between inflammation and mood pathologies. Knowledge of these cytokine profiles might lead to novel treatment approaches that target inflammation as an element of therapy for depression.

Cytokine storms have been an extreme manifestation of the focus on understanding the hyper-expression of pro-inflammatory cytokines during viral infections. Tisoncik et al. (2012) describe the possible implications of cytokine kinetics on disease pathology and provide rational priority in the treatment regimen, specifically immunomodulatory therapies to counteract the ill effects of excessive cytokine overproduction. This is the situation in COVID-19 infection which has been brought out by Conti et al. (2020) who present evidence supporting that the virus induces and promotes the release of pro-inflammatory cytokines. Treatments directed

against these cytokines may result in better clinical outcomes among patients with severe viral infections. Finally, members of the IL-10 family of cytokines play a central role in the regulation of immune responses during infection. The significance of these cytokines in modulating inflammation and promoting healing provides avenues for potential therapeutic applications in inflammatory diseases. Several gaps of knowledge remain in the cytokine storm despite extensive researches. For example, although the involvement of distinct cytokines in the path of the disease is recognized, the molecular pathways that provoke a cytokine storm during SARS-CoV-2 infection have not been clearly described, if at all (Azkur et al., 2020). More importantly, the specific mechanisms through which the initiation of cytokine storms is triggered in different individuals remain unknown. Such variability in patients' responses to immunomodulatory therapies will require further study to identify biomarkers that predict therapeutic efficacy. Future research should focus on longitudinal studies with patients to follow cytokine profiles from the time of infection through recovery or decline. Additionally, the duality of immune suppression and hyper-inflammation is complicated and more research is needed to determine how it works (Kim et al., 2021). Future studies should concentrate on tools for diagnostics that will correctly characterize immune responses in covid-19 patients, particularly regarding cytokine levels and immune function. In addition to this, the therapeutic approach of new anti-inflammatory agents and their mode of action may enlighten the effective management strategy of cytokine storm beyond COVID-19, which may be beneficial for such patients suffering from other hyper-inflammatory conditions (Yang et al., 2021).

UNDERSTANDING CYTOKINE STORMS

These conditions are linked to overproduction or unregulated release of pro-inflammatory cytokines causing severe inflammation and damage to normal tissues. A recent position paper by Mehta et al. (2020) highlights the need for the identification of cytokine storm syndromes in COVID-19 with the possibility of immunosuppression as a treatment option to check hyper-inflammatory responses conducting to outcomes in the form of acute respiratory distress syndrome (ARDS) and multi-organ failure. Such effects are seen since the high inflammatory response induced by the SARS-CoV-2 virus leads to hyper-inflammatory lung disease, which results in more lung pathology and is related to worse outcome measures in patients.

On the other hand, clinical outcomes are very much determined by an interplay between cytokines, particularly IL-6, IL-10, and TNFα. High levels of cytokines have been identified to correlate strongly with the worst outcomes for COVID-19 patients; it further highlights the need for a deeper understanding of the mechanisms of a cytokine storm for effective therapeutic strategies. Pathological features associated with these storms were elaborated on by Hu et al. (2020) who noted that immune cell infiltration into lung tissues greatly increases the severity of the disease, which manifests in high mortality rates.

Cytokine storm clinical symptoms in COVID-19 patients are dramatic. Therefore, in this study, Soy et al. (2020), the level of cytokines including IL-6 and IL-1β relate to the severity of disease manifestations, which includes ARDS and multi-organ failure. A high production of these cytokines is seen as an indicator of dysfunctional regulation of the inflammatory response, which otherwise becomes challenging to differentiate the fine line between the onset of an appropriate immune reaction and an overly vigorous one. Sinha et al. (2020) discusses with importance ongoing clinical trials on immune-targeted therapies in treatment against cytokine storm effects, thus accusing more characterization of patient leucocytes and cytokine profiles in understanding mechanisms that drive symptomatic association with storm syndrome as a guide to treatment strategies.

PATHOPHYSIOLOGICAL MECHANISMS

The pathophysiology mechanisms of cytokine storms showcase the immune dysregulation complexities whereby the body's response to infection becomes maladaptive. Coperchini et al. consider chemokine and chemokine-receptor systems in the overview of cytokine storm. They point to specific paths that can be used as therapeutic targets. Regarding the interaction between inflammation and coagulation, it was discussed by José and Manuel. They believe that the cytokine storm not only precedes respiratory failure but also increases the risk of thrombotic events further complicated by this multisystem approach to pathophysiology. Dual role for the immune system in COVID-19, as described by Pedersen and Ho. An initial protective immune response is eventually replaced by a pathogenic hyper-inflammatory response. An understanding of that balance holds essential value in the development of targeted therapies that can restore immune function without exacerbating inflammation.

Channappanavar and Perlman (2017) described the cytokine storm as the leading aspect of COVID-19 pathogenesis in which uncontrolled immune responses cause hyperinflammation, acute respiratory distress syndrome, and finally multi-organ failure. They stress specific features such as severe lymphopenia and striking lung pathology in patients that are highly correlated with the cytokine storm, truly accentuating its contribution to disease severity. This was detailed by Azkur et al. (2020) how certain individual cytokines like TNF-α and IFN-γ are important drivers of a novel form of inflammatory cell demise termed PANoptosis, resulting in increased destruction of tissues during COVID-19 patient pathogenesis. Further investigation by Karki et al. (2020) on the concerted actions of TNF-α and IFN-γ proved that combined action does indeed exist, causing inflammatory cell death as well as being associated with increased disease fatality.

THERAPEUTIC INTERVENTIONS

In particular, the treatment of cytokine storms has gained considerable momentum toward the immunomodulatory agents. Various studies have therefore palpated the capacity of mesenchymal stem cells in ameliorating cytokine storms. The results restore an efficient immune response with what seems a marked reduction in inflammation, hence presenting MSCs as a promising avenue of therapy for critically ill patients of COVID-19. In addition, IL-6 and general cytokine inhibitors are showing promise in the clinic. Hence, the work by Tang et al. (2020) supports that individualized therapy may significantly change the prognosis of patients who are by far gravely hit by a cytokine storm. However, this does depend on how one determines such a patient.

The landscape of therapeutics for managing cytokine storms is racing at a fast pace. It is for this reason that provides discussion on various immunopathological mechanisms and clinical considerations in the treatment of cytokine storm and thus also builds the grounds that anti-inflammatory agents may play an important role in the management of severe COVID-19. Further treatment avenues are suggested in the work by highlighting possible therapeutic strategies, such as cytokine-targeted therapies and extracorporeal cytokine removal, which could effectively damp hyper-inflammation and boost patients' chances of survival.

CONCLUSION

In summary, cytokines are critical disease pathogenesis mediators for most diseases and increased understanding of their functions may lead to new treatment approaches. Further study on the kinetics of cytokines is vital in developing some targeted interventions that can better improve the outcome of patients with varied health conditions. For the severe COVID-19 cases, which have come up as a big problem with patient outcome and mortality, the intervention of cytokine storms is massive. Without a shadow of a doubt, understanding how it all works and brand-new treatments is the only way forward for an improvement in clinical care and real interventions for treatment. This area needs further investigation to achieve further improvement and development in dealing with infectious diseases.

REFERENCES

1) Akhmerov, A.., & Marbán, E. (2020). COVID-19 and the Heart. *Circulation Research*, 126. http://doi.org/10.1161/CIRCRESAHA.120.317055
2) Atri, C.., Guerfali, F.., & Laouini, D. (2018). Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. *International Journal of Molecular Sciences*, 19. http://doi.org/10.3390/ijms19061801
3) Azkur, A. K.., Akdiş, M.., Azkur, D.., Sokolowska, M.., Veen, W. van de., Brüggen, M.., O'Mahony, L.., Gao, Yadong., Nadeau, K.., & Akdis, C. (2020). Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 75, 1564 - 1581. http://doi.org/10.1111/all.14364
4) Bhaskar, S.., Sinha, A.., Banach, Maciej., Mittoo, S.., Weissert, Robert., Kass, J.., Rajagopal, Santhosh K.., Pai, Anupama R., & Kutty, S. (2020). Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. *Frontiers in Immunology*, 11. http://doi.org/10.3389/fimmu.2020.01648
5) Catanzaro, M.., Fagiani, F.., Racchi, M.., Corsini, E.., Govoni, S.., & Lanni, C. (2020). Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. *Signal Transduction and Targeted Therapy*, 5. http://doi.org/10.1038/s41392-020-0191-1
6) Channappanavar, Rudragouda., & Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Seminars in Immunopathology*, 39, 529 - 539. http://doi.org/10.1007/s00281-017-0629-x
7) Chousterman, B.., Swirski, F.., & Weber, G.. (2017). Cytokine storm and sepsis disease pathogenesis. *Seminars in Immunopathology*, 39, 517 - 528 . http://doi.org/10.1007/s00281-017-0639-8
8) Conti, P.., Ronconi, G.., Caraffa, A.., Gallenga, C.., Ross, R.., Frydas, I.., & Kritas, S.. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.. *Journal of Biological Regulators and Homeostatic Agents* , 34 , 327-331 . http://doi.org/10.23812/CONTI-E
9) Coperchini, F.., Chiovato, L.., Croce, L.., Magri, F.., & Rotondi, M.. (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine & Growth Factor Reviews* , 53 , 25 - 32 . http://doi.org/10.1016/j.cytogfr.2020.05.003
10) Dinarello, C.. (2018). Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunological Reviews* , 281 , 27 - 8 . http://doi.org/10.1111/imr.12621
11) Fajgenbaum, D.., & June, C.. (2020). Cytokine Storm. *The New England Journal of Medicine* , 383 , 2255 - 2273 . http://doi.org/10.1056/NEJMra2026131
12) Hu, B.., Huang, Shaoying., & Yin, L.. (2020). The cytokine storm and COVID-19. *Journal of Medical Virology* , 93 , 250 - 256 . http://doi.org/10.1002/jmv.26232

13) José, R.., & Manuel, A.. (2020). COVID-19 cytokine storm: the interplay between inflammation and coagulation. *The Lancet. Respiratory Medicine* . http://doi.org/10.1016/S2213-2600(20)30216-2
14) Kapoor, M.., Martel-Pelletier, J.., Lajeunesse, D.., Pelletier, J.., & Fahmi, H.. (2011). Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nature Reviews Rheumatology* , 7 , 33-42 . http://doi.org/10.1038/nrrheum.2010.196
15) Karki, Rajendra., Sharma, B.., Tuladhar, Shraddha., Williams, E. P.., Zalduondo, Lillian., Samir, Parimal., Zheng, Min., Sundaram, Balamurugan., Banoth, B.., Malireddi, R.., Schreiner, P.., Neale, G.., Vogel, P.., Webby, R.., Jonsson, C.., & Kanneganti, T.. (2020). Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. *bioRxiv* . http://doi.org/10.1101/2020.10.29.361048
16) Kim, Jae Seok., Lee, Jun Young., Yang, Jae-Won., Lee, Keumwha., Effenberger, M.., Szpirt, W.., Kronbichler, A.., & Shin, J.. (2021). Immunopathogenesis and treatment of cytokine storm in COVID-19. *Theranostics* , 11 , 316 - 329 . http://doi.org/10.7150/thno.49713
17) Köhler, C.., Freitas, T. H.., Maes, M.., Andrade, N. Q. de., Liu, C.., Fernandes, Brisa., Stubbs, B.., Solmi, M.., Veronese, N.., Herrmann, N.., Raison, C.., Miller, B. J.., Lanctôt, K.., & Carvalho, A.. (2017). Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatrica Scandinavica* , 135 . http://doi.org/10.1111/acps.12698
18) Landskron, G.., Fuente, M. De la., Thuwajit, P.., Thuwajit, C.., & Hermoso, M.. (2014). Chronic Inflammation and Cytokines in the Tumor Microenvironment. *Journal of Immunology Research* , 2014 . http://doi.org/10.1155/2014/149185
19) Libby, P.. (2012). Inflammation in Atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology* , 32 , 2045–2051 . http://doi.org/10.1161/ATVBAHA.108.179705
20) Liu, Ting., Zhang, Lingyun., Joo, Donghyun., & Sun, Shao-Cong. (2017). NF-κB signaling in inflammation. *Signal Transduction and Targeted Therapy* , 2 . http://doi.org/10.1038/sigtrans.2017.23
21) Makki, Kassem., Froguel, P.., & Wolowczuk, I.. (2013). Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. *ISRN Inflammation* , 2013 . http://doi.org/10.1155/2013/139239
22) Mangan, M.., Mangan, M.., Olhava, E.., Roush, W.., Seidel, H.., Glick, G.., & Latz, E.. (2018). Targeting the NLRP3 inflammasome in inflammatory diseases. *Nature Reviews Drug Discovery* , 17 , 588-606 . http://doi.org/10.1038/nrd.2018.97
23) Mehta, P.., McAuley, D.., Brown, Michael., Sanchez, Emilie., Tattersall, R.., & Manson, J.. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London, England)* , 395 , 1033 - 1034 . http://doi.org/10.1016/S0140-6736(20)30628-0
24) Neurath, M.. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology , 14 , 329-342 . http://doi.org/10.1038/nri3661
25) Ouyang, W.., Rutz, S.., Crellin, N.., Valdez, P.., & Hymowitz, S.. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease.. *Annual review of immunology* , 29 , 71-109 . http://doi.org/10.1146/annurev-immunol-031210-101312
26) Pedersen, Savannah F.., & Ho, Y.. (2020). SARS-CoV-2: A Storm is Raging.. *The Journal of clinical investigation* . http://doi.org/10.1172/JCI137647
27) Ragab, D.., Eldin, Haitham Salah., Taeimah, M.., Khattab, R.., & Salem, R.. (2020). The COVID-19 Cytokine Storm; What We Know So Far. *Frontiers in Immunology* , 11 . http://doi.org/10.3389/fimmu.2020.01446
28) Schulert, G.., & Grom, A.. (2015). Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.. *Annual review of medicine* , 66 , 145-59 . http://doi.org/10.1146/annurev-med-061813-012806
29) Shimabukuro-Vornhagen, A.., Gödel, P.., Subklewe, M.., Stemmler, H.., Schlößer, H.., Schlaak, M.., Kochanek, M.., Böll, B.., & Bergwelt-Baildon, M. von. (2018). Cytokine release syndrome. *Journal for Immunotherapy of Cancer* , 6 . http://doi.org/10.1186/s40425-018-0343-9
30) Sinha, P.., Matthay, M.., & Calfee, C.. (2020). Is a "Cytokine Storm" Relevant to COVID-19?. *JAMA internal medicine* . http://doi.org/10.1001/jamainternmed.2020.3313
31) Soy, M.., Keser, G.., Atagündüz, P.., Tabak, F.., Atagündüz, I.., & Kayhan, S.. (2020). Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. *Clinical Rheumatology* , 39 , 2085 - 2094 . http://doi.org/10.1007/s10067-020-05190-5
32) Sproston, Nicola R.., & Ashworth, J.. (2018). Role of C-Reactive Protein at Sites of Inflammation and Infection. *Frontiers in Immunology* , 9 . http://doi.org/10.3389/fimmu.2018.00754
33) Tang, Yujun., Liu, Jiajia., Zhang, Dingyi., Xu, Zhenghao., Ji, Jinjun., & Wen, Chengping. (2020). Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Frontiers in Immunology* , 11 . http://doi.org/10.3389/fimmu.2020.01708

34) Tisoncik, J.., Korth, M. J.., Simmons, C.., Farrar, J.., Martin, T.., & Katze, M.. (2012). Into the Eye of the Cytokine Storm. *Microbiology and Molecular Biology Reviews* , 76 , 16 - 32 . http://doi.org/10.1128/MMBR.05015-11

35) Wang, Jin., Jiang, Mengmeng., Chen, Xin., & Montaner, L.. (2020). Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *Journal of Leukocyte Biology* , 108 , 17 - 41 . http://doi.org/10.1002/JLB.3COVR0520-272R

36) Warnatsch, A.., Ioannou, M.., Wang, Qian., & Papayannopoulos, V.. (2015). Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. *Science* , 349 , 316 - 320 . http://doi.org/10.1126/science.aaa8064

37) Wojdasiewicz, Piotr., Poniatowski, Łukasz A., & Szukiewicz, D.. (2014). The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis. *Mediators of Inflammation* , 2014 . http://doi.org/10.1155/2014/561459

38) Yang, Lan., Xie, Xueru., Tu, Zikun., Fu, Jinrong., Xu, Damo., & Zhou, Yufeng. (2021). The signal pathways and treatment of cytokine storm in COVID-19. *Signal Transduction and Targeted Therapy* , 6 . http://doi.org/10.1038/s41392-021-00679-0

39) Ye, Q.., Wang, Bili., & Mao, Jian-hua. (2020). The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. *The Journal of Infection* , 80 , 607 - 613 . http://doi.org/10.1016/j.jinf.2020.03.037

40) Zhao, Huakan., Wu, Lei., Yan, Guifang., Chen, Yu., Zhou, Mingyue., Wu, Yongzhong., & Li, Yongsheng. (2021). Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduction and Targeted Therapy* , 6 . http://doi.org/10.1038/s41392-021-00658-5